Inovio receives FDA accelerated approval for VOCERYQ, a DNA immunotherapy for adult RRP
+1 new source since this summary was written
Inovio Pharmaceuticals announced that the U.S. Food and Drug Administration granted accelerated approval to VOCERYQ, a DNA‑based immunotherapy for adults with recurrent respiratory papillomatosis (RRP). The approval rests on a Phase 1/2 trial in which 27% of patients required no surgery for 12 months after treatment. The company plans to make the product available for order within about 60 days and to launch commercially in the first quarter of 2027, subject to a confirmatory study required for continued approval.
Why it matters
The approval creates a new revenue stream for Inovio as it introduces its first FDA‑approved DNA medicine, but investors should watch the outcome of the confirmatory study that will determine whether the approval is sustained.
Key facts
- 1The FDA granted accelerated approval to VOCERYQ based on a complete response rate of 27% in the primary efficacy population. finance.yahoo.com
- 2The pivotal RRP‑001 study enrolled 32 adults, with 26 patients forming the primary efficacy analysis set. finance.yahoo.com
- 3Patients in the efficacy set had a median of 4.5 surgeries in the year before treatment, ranging from three to eight. finance.yahoo.com
- 4Inovio expects VOCERYQ to be available for ordering and shipment within approximately 60 days of the approval announcement. finance.yahoo.com
- 5A full commercial launch is planned for the first quarter of 2027. finance.yahoo.com
- 6Inovio must submit a draft protocol for the required confirmatory study by the end of 2026, with a final protocol expected by mid‑2027. finance.yahoo.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.